Eli Lilly and Company to Build Four New Pharmaceutical Manufacturing Sites in the United States

On Feb. 26, Eli Lilly and Company announced at a press conference in Washington, D.C., plans to reinforce its domestic medicine production across therapeutic areas by building four new pharmaceutical manufacturing sites in the United States.

A press release on the announcement said, “This brings the company's total U.S. capital expansion commitments to more than $50 billion since 2020.”

Further, “Three of the future U.S. sites announced today will focus on manufacturing active pharmaceutical ingredients (API), reshoring critical capabilities of small molecule chemical synthesis and further strengthening Lilly's supply chain. The fourth location will extend the company's global parenteral manufacturing network for future injectable therapies.”

At the four new sites, Lilly anticipates creating more than 3,000 jobs for engineers, scientists, operations personnel and lab technicians. Lily also said in the press release that it could create almost 10,000 construction jobs during the development of the sites.

The press release added, “Expected additional economic benefits of these new sites to the selected communities include increased local spending, tax revenue, economic diversification, improved infrastructure, population growth, and training and development opportunities.”